SCHEDULE 13G/A: Panacea Venture Funds Disclose 5.5% Stake in Adagene Inc. Ordinary Shares
Beneficial Ownership Report
Panacea Venture Healthcare Fund II, L.P., along with its related entities and principal James Huang, has disclosed a 5.5% beneficial ownership stake in Adagene Inc.'s Ordinary Shares as of December 31, 2024.
Summary
- Panacea Venture Healthcare Fund II, L.P., Panacea Venture Healthcare Fund II GP Company, Ltd., Panacea Innovation Limited, and James Huang collectively reported beneficial ownership of 3,037,500 Ordinary Shares of Adagene Inc.
- This aggregate amount represents 5.5% of Adagene Inc.'s Ordinary Shares outstanding, based on 55,338,480 shares as of June 30, 2024.
- The reporting persons share both voting and dispositive power over all 3,037,500 shares.
- James Huang is the sole owner of Panacea Innovation Limited, which in turn solely owns Panacea Venture Healthcare Fund II GP Company, Ltd., the general partner of Panacea Venture Healthcare Fund II, L.P.
- Despite the shared beneficial ownership, each reporting person disclaims such beneficial ownership.
- The filing is an Amendment No. 2 to a Schedule 13G, indicating a previous filing of beneficial ownership.
Sentiment
Score: 5
Explanation: The document is a factual compliance filing (Schedule 13G) reporting beneficial ownership. It does not contain information that inherently conveys positive or negative sentiment regarding the issuer's performance or outlook. The disclosure of a 5.5% stake by an institutional investor is a neutral event in terms of sentiment, though it is a material holding.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant passive investment in a publicly traded company within the biotechnology or healthcare sector. It does not provide specific insights into broader industry trends or competitive positioning beyond the fact of the investment itself.
Stakeholder Impact
- Shareholders: The disclosure of a significant 5.5% stake by an institutional investor group may be of interest to existing and potential shareholders, indicating a notable investment in the company.
Key Dates
| Date | Description |
|---|---|
| 2024-06-30 | Date of Ordinary Shares outstanding (55,338,480) as disclosed in Issuer's Form 6-K. |
| 2024-12-31 | Date of event which requires filing of this statement, representing the 'as of' date for the reported beneficial ownership. |
| 2025-02-14 | Date the Schedule 13G Amendment No. 2 was filed with the SEC. |
Keywords
Adagene Inc., Panacea Venture Healthcare Fund II, Beneficial Ownership, SEC Filing, Schedule 13G, Ordinary Shares, Institutional Investor, Biotechnology, Healthcare Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.